Nykode Therapeutics AS (OSL:NYKD)
Norway
· Delayed Price · Currency is NOK | Market Cap | 1.07B |
| Revenue (ttm) | 4.57M |
| Net Income (ttm) | -123.39M |
| Shares Out | 326.55M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 1.00 (30.54%) |
| Ex-Dividend Date | n/a |
| Volume | 1,607,565 |
| Average Volume | 1,524,793 |
| Open | 3.272 |
| Previous Close | 3.274 |
| Day's Range | 3.180 - 3.590 |
| 52-Week Range | 1.440 - 4.100 |
| Beta | 1.17 |
| RSI | 49.79 |
| Earnings Date | Feb 25, 2026 |
About Nykode Therapeutics AS
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i... [Read more]
Financial Performance
In 2025, Nykode Therapeutics AS's revenue was $453,000, a decrease of -95.05% compared to the previous year's $9.16 million. Losses were -$12.24 million, -68.47% less than in 2024.
Financial numbers in USD Financial StatementsNews
Nykode Therapeutics AS 2025 Q4 - Results - Earnings Call Presentation
2026-02-25. The following slide deck was published by Nykode Therapeutics AS in conjunction with their 2025 Q4 earnings call.
Q4 2025 Nykode Therapeutics ASA Earnings Call Transcript
Q4 2025 Nykode Therapeutics ASA Earnings Call Transcript
Nykode Therapeutics AS 2025 Q3 - Results - Earnings Call Presentation
Q3 2025 Nykode Therapeutics ASA Earnings Call Transcript
Q3 2025 Nykode Therapeutics ASA Earnings Call Transcript
Nykode Therapeutics AS (VACBF) Q3 2025 Earnings Call Transcript
Nykode Therapeutics AS (OTCPK:VACBF) Q3 2025 Earnings Call November 24, 2025 9:00 AM EST Company Participants Michael Engsig - Chief Executive Officer Agnete Fredriksen - Co-Founder & Chief Scientific...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at PEGS Europe
OSLO, Norway, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines
OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting
OSLO, Norway, June 20, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy
OSLO, Norway, June 11, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, toda...
Nykode Therapeutics - Quarterly report Q1 2024
OSLO, Norway, May 14, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, toda...
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
OSLO, Norway, April 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, to...
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
OSLO, Norway, March 21, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, to...
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases
OSLO, Norway, March 19, 2024 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, to...
Nykode Therapeutics - Quarterly report Q3 2023
OSLO, Norway, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...
Nykode Therapeutics to Present at the mRNA Cancer Vaccines Summit 2023 in Boston
OSLO, Norway, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, tod...